Recent articles from Anastasiia
Trially AI Raises $4.7M Seed Round, Launches AI for Clinical Trial Enrollment
Trially AI has secured $4.7 million in seed financing led by Flyover Capital, with participation from Alpaca, Atria, Blu Ventures, Looking Glass Capital, Redbud, The Council, and Gaingels. The company also launched Margo, an agentic AI system designed …
Helmholtz Munich and Parse Biosciences Partner to Build Largest Human Lung Tissue Perturbation Atlas
Helmholtz Munich and Parse Biosciences have launched a collaboration to generate an atlas of human lung tissue perturbations. The project uses Parse’s GigaLab single-cell sequencing platform to examine how healthy and diseased lung tissues respond to 900 different pharmacological interventions, …
Immuto Raises $8M Seed for AI Structural Surfaceomics, Enters Daiichi Sankyo Oncology Collaboration
Immuto Scientific has closed an oversubscribed $8 million Seed 2 financing round led by DYDX, with participation from WARF Ventures, Gravity Fund, and Great Oaks Venture Capital, among others, and entered a drug discovery collaboration with Daiichi Sankyo. The …
Enveda Starts Phase 1b of AI-Discovered Small-Molecule Anti-Inflammatory for Atopic Dermatitis
Dr. Vince Clinical Research, based in Overland Park, Kansas, specialized in early phase and multi-site clinical trials across therapeutic areas including neuroscience, infectious diseases, and cardiometabolic disorders, has announced that the first patient has been dosed in a Phase …
UK Health-AI Push: NVIDIA Partnerships Back Sovereign Models from Imaging to Drug Design
NVIDIA is working with UK universities, research centers, and technology companies on applying AI across life sciences, robotics, healthcare, and generative model development. These collaborations form part of the UK’s efforts to build sovereign AI — the capability to develop …
Lantern Pharma Reports AI-Guided LP-184 Meets Phase 1a Endpoints in Solid Tumors
Lantern Pharma, an oncology-focused company that applies artificial intelligence to drug development, has completed its Phase 1a trial of LP-184 in 63 patients with relapsed or refractory solid tumors, including glioblastoma. The study met all primary objectives, showing a …
Biomni and Sage Partner on AI-Powered Access to Biomedical Data
Sage Bionetworks and Biomni have announced a collaboration that connects researchers to approximately 3 petabytes of curated biomedical datasets through natural language queries. The integration is designed to simplify discovery across fragmented repositories and reduce time spent on manual data …
Medra Launches AI-Driven Platform for Continuous Scientific Experimentation
Medra, a San Francisco–based startup, has unveiled its Continuous Science Platform, a system designed to accelerate experimental research by integrating robotics with proprietary AI models. The platform is presented as a response to persistent data scarcity in scientific …
Tempus AI Validates RNA-Based Algorithm for Pancreatic Cancer Therapy Selection
Tempus has reported results validating its PurIST algorithm as a biomarker to guide chemotherapy choice in advanced pancreatic ductal adenocarcinoma (PDAC). The study reportedly represents the largest real-world analysis of its kind and provides evidence for integrating PurIST into …
XtalPi and PharmaEngine Get Approvals for Phase I Trial of AI-Designed PRMT5 Inhibitor
XtalPi and PharmaEngine have received clearance from regulators in Taiwan and Australia to begin first-in-human testing of PEP08, an AI-designed second-generation PRMT5 inhibitor targeting solid tumors. The milestone also triggered a payment to XtalPi under the collaboration agreement between the …